NPM1 and acute myeloid leukemia: In particular, the m6A demethylase FTO is reported to be highly expressed in certain AML subtypes, including those carrying t(15;17)/PML-RARA, t(11q23)/MLL-rearrangements, NPM1, or FLT3-ITD mutations, and promote leukemogenesis by regulating its mRNA targets, especially RARA and ASB2, through m6A demethylation [18].